Biosimilars

Intas biosimilar portfolio consists of 13 commercialized products and a promising pipeline, covering 6 therapeutical areas. These products are developed and manufactured at Intas’ biotechnology facility in India, which is currently approved by the European, Canadian, Australian and Brazilian regulatory agencies among others.

Biosimilar

To view our Biosimilars specific dossier portfolio, Please visit our app.
Musculo-Skeletal System
Oncology
Immunosupression & Autoimmune Diseases
Hematology
Ophtalmology
Hormonal System
Biosimilars
To view our Biosimilars specific dossier portfolio, Please visit our app.
Please click here

High-quality standards, certified by 15 countries.

First EU approved facility in India.

Commercialized in 30+ countries and under registration in many others.

Fully integrated process

Our Biopharmaceuticals site has more than 16 years of experience in the development and manufacturing of multiple biopharmaceutical products with the first product launched in 2004.

It operates in approximately 15,500m² and multiple expansion plans have been undertaken since 2012 (when disposable bioreactors for mammalian cell cultures were included) to become one of India’s largest biopharmaceutical fermentation plants.